摘要
目的观察前列腺素E1(PGE1)对心力衰竭病人的治疗效果,同时通过血小板上EP受体改变,探讨其可能机制。方法 86例病人被随机分为两组:常规治疗组(A组)48例,PGE1治疗组(B组)38例。常规治疗组采用目前常规抗心力衰竭治疗,而治疗组加用了PGE120μg于5%葡萄糖注射液稀释后泵静注14d为1个疗程。以治疗前后心功能改善作为判断标准,同时用PCR法测定血小板上EP受体改变。结果 B组总有效率为92.11%,显著高于A组75.00%,差异有统计学意义(χ2=3.86,P<0.05);PGE1治疗的慢性阻塞性肺病、高血压和冠心病病人疗效比较,差异无统计学意义(χ2=0.50,P>0.05);B组治疗后EP2和EP4水平显著增高,与治疗前比较,差异有统计学意义(t分别=7.86、3.92,P均<0.05)。结论 PGE1对慢性阻塞性肺病、高血压和冠心病所致的心力衰竭有较好的疗效,其机制可能与治疗后EP2和EP4受体表达增加有关。
Objective To observe the effects of prostaglandin E1 on heart failure treatment, to explore its possible mechanism through changes of EP receptors on platelet. Methods A total of 86 patients were randomly divided into two groups： the conventional treatment group（group A） of 48 cases, and PGE1 treatment group（group B） of 38 cases. Group A used conventional anti-heart failure therapy, while group B had PGE1 20 pLg diluted in 5% GS intravenous pump 14 days for a course of treatment. Heart function was improved after treatment as the criterion. Changes of EP receptor on the platelet were detected by PCR method. Results The total effective rate in group B was significantly higher than that of the group A （92.11% vs. 75.00%; χ2=3.86 ,P〈0.05）. The effective rate did not have significantly difference in heart failure patients caused by COPD, hypertension and coronary heart disease （χ2=0.50,P〉0.05）. EP2 and EP4 levels were significantly increased after treatment in group B （t=7.86,3.92,P〈0.05）. Conclusions PGE1 have good effects on heart failure caused by COPD, hypertension and coronary heart disease, which may be related with EP2 and EP4 receptor expression increased after the treatment.
出处
《全科医学临床与教育》
2012年第1期31-33,共3页
Clinical Education of General Practice
基金
浙江省义乌市科学技术局(07-3-03)
